Replies to post #1812 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

2007-2008 News Flow

Oct 07: Start dosing in IDX-899 phase-1b monotherapy trial.

Nov 07: Data from selected Tyzeka post-marketing studies at AASLD conference.

Nov 07: 3Q07 financial results and CC.

4Q07: Preliminary data from IDX899 phase-1b trial.

4Q07: File IND for IDX102 or IDX184 second-generation HCV nucleoside analogs.

Feb 08: IDX899 phase-1b data at CROI conference.

Mar 08: 4Q07 financial results and CC with 2008 financial guidance.

May 08: Expiration of NVS-IDIX standstill agreement.

4Q08: File IND’s for HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor.